Fri, November 5, 2010
Thu, November 4, 2010
Wed, November 3, 2010
Tue, November 2, 2010
Mon, November 1, 2010
Sat, October 30, 2010
Fri, October 29, 2010
Thu, October 28, 2010
Wed, October 27, 2010
Tue, October 26, 2010
Mon, October 25, 2010
Sun, October 24, 2010
Sat, October 23, 2010
Fri, October 22, 2010
Thu, October 21, 2010
Wed, October 20, 2010
[ Wed, Oct 20th 2010 ]: Market Wire
STJ, AGAM, BAC, MDT, BSX
Tue, October 19, 2010
Mon, October 18, 2010

ARIAD to Present at the Oppenheimer & Co. 21st Annual Healthcare Conference


  Copy link into your clipboard //health-fitness.news-articles.net/content/2010/ .. heimer-co-21st-annual-healthcare-conference.html
  Print publication without navigation Published in Health and Fitness on by Market Wire


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ ARIAD Pharmaceuticals, Inc. ] (NASDAQ: ARIA) today announced that it is scheduled to present at the Oppenheimer & Co. 21st Annual Healthcare Conference being held at the Waldorf=Astoria Hotel in New York City. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Tuesday, November 2, 2010 at 10:15 a.m. (ET).

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at [ http://investor.ariad.com ]. A replay of the presentation will be available on the ARIAD website approximately 24 hours after the presentation and will be archived for three weeks.

About ARIAD

ARIADa™s vision is to transform the lives of cancer patients with breakthrough medicines. The Companya™s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need a" aggressive cancers where current therapies are inadequate. ARIADa™s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor being developed by Merck Sharpe & Dohme Corp. and is in Phase 3 clinical development in patients with advanced sarcomas. ARIADa™s second internally discovered product candidate, ponatinib, is an investigational pan-BCR-ABL inhibitor in a pivotal Phase 2 clinical trial in patients with chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia. For additional information about the Company, please visit [ http://www.ariad.com ].


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear